10/24
08:21 am
ango
AngioDynamics launches long-term study of NanoKnife for prostate cancer [Yahoo! Finance]
Low
Report
AngioDynamics launches long-term study of NanoKnife for prostate cancer [Yahoo! Finance]
10/23
02:15 pm
ango
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE [Yahoo! Finance]
Low
Report
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE [Yahoo! Finance]
10/23
08:00 am
ango
AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
Medium
Report
AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
10/22
10:56 am
ango
AngioDynamics' NanoKnife System gains CPT codes for prostate and liver treatments [Yahoo! Finance]
Medium
Report
AngioDynamics' NanoKnife System gains CPT codes for prostate and liver treatments [Yahoo! Finance]
10/21
08:00 am
ango
AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
Medium
Report
AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
10/4
01:35 pm
ango
AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Low
Report
AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
10/4
11:36 am
ango
AngioDynamics, Inc. (NASDAQ: ANGO) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $13.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
AngioDynamics, Inc. (NASDAQ: ANGO) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $13.00 to $12.00. They now have a "buy" rating on the stock.
10/3
03:20 pm
ango
AngioDynamics slides after Q1 revenue miss [Seeking Alpha]
Medium
Report
AngioDynamics slides after Q1 revenue miss [Seeking Alpha]
10/3
11:34 am
ango
Why AngioDynamics Stock Is Crashing Today [Yahoo! Finance]
Low
Report
Why AngioDynamics Stock Is Crashing Today [Yahoo! Finance]
10/3
10:34 am
ango
AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript [Seeking Alpha]
10/3
06:44 am
ango
AngioDynamics: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
High
Report
AngioDynamics: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
10/3
06:30 am
ango
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
High
Report
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
9/30
10:07 am
ango
Here's What Could Help AngioDynamics (ANGO) Maintain Its Recent Price Strength [Yahoo! Finance]
Low
Report
Here's What Could Help AngioDynamics (ANGO) Maintain Its Recent Price Strength [Yahoo! Finance]
9/23
11:11 am
ango
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe [Yahoo! Finance]
Low
Report
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe [Yahoo! Finance]
9/20
08:12 am
ango
AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Low
Report
AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
9/20
06:47 am
ango
AngioDynamics initiates thrombectomy system trial across Europe [Yahoo! Finance]
Low
Report
AngioDynamics initiates thrombectomy system trial across Europe [Yahoo! Finance]
9/19
04:49 pm
ango
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes [Yahoo! Finance]
Medium
Report
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes [Yahoo! Finance]
9/19
04:40 pm
ango
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
Low
Report
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
9/19
08:00 am
ango
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
Low
Report
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
9/17
08:39 am
ango
This AngioDynamics Insider Increased Their Holding In The Last Year [Yahoo! Finance]
Low
Report
This AngioDynamics Insider Increased Their Holding In The Last Year [Yahoo! Finance]
9/4
12:32 pm
ango
AngioDynamics Stock Falls Despite CE Mark for Auryon System [Yahoo! Finance]
Low
Report
AngioDynamics Stock Falls Despite CE Mark for Auryon System [Yahoo! Finance]
9/4
07:19 am
ango
AngioDynamics wins EU CE mark for Auryon system to treat PAD [Yahoo! Finance]
Low
Report
AngioDynamics wins EU CE mark for Auryon system to treat PAD [Yahoo! Finance]
9/3
08:30 am
ango
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
Medium
Report
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
8/27
01:19 pm
ango
AngioDynamics (ANGO) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]
Neutral
Report
AngioDynamics (ANGO) Upgraded to Strong Buy: Here's Why [Yahoo! Finance]
8/27
04:39 am
ango
Renal Dialysis Market Outlook, 2028 - Global and Regional-Level Analysis and Forecasts for Hemodialysis, Peritoneal, and Other Types of Renal Dialysis by End-user (In-Center, Home), Featuring ~25 Major Players [Yahoo! Finance]
Low
Report
Renal Dialysis Market Outlook, 2028 - Global and Regional-Level Analysis and Forecasts for Hemodialysis, Peritoneal, and Other Types of Renal Dialysis by End-user (In-Center, Home), Featuring ~25 Major Players [Yahoo! Finance]